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Stlmmary 
CD28 is an adhesion receptor expressed as a 44-kD dimer on the surface of a major subset of 
human T cells. The CD28 receptor regulates the production of multiple lymphokines, including 
interleukin 2 (Ib2), by activation of a signal transduction pathway that is poorly understood. 
Here we show that ligation of CD28 by a monoclonal antibody (mAb) or by a natural ligand, 
B7/BB1, induces protein tyrosine phosphorylation that is distinct from T cell receptor (TCR)- 
induced tyrosine phosphorylation. CD28-induced protein tyrosine phosphorylation was greatly 
enhanced in cells that had been preactivated by ligation of the TCR, or by pretreatment with 
phorbol esters. Rapid and prolonged tyrosine phosphorylation of a single substrate,  ppl00, was 
induced in T cells after interaction with B7/BB1 presented on transfected Chinese hamster ovary 
(CHO) cells. Anti-B7 mAb inhibited B7/BB1 receptor-induced tyrosine phosphorylation, indicating 
that B7-CD28 interaction was required. CD28-induced tyrosine phosphorylation was independent 
of the TCR because it occurred in a variant of the Jurkat T cell line that does not express the 
TCR. Herbimycin A, a protein tyrosine kinase inhibitor, could prevent CD28-induced tyrosine 
phosphorylation and  CD28-induced  I1.-2 production in  normal T  cells. The  simultaneous 
crosslinking of CD28 and CD45, a tyrosine phosphatase, could prevent tyrosine phosphorylation 
of ppl00. These results suggest that specific tyrosine phosphorylation, particularly of ppl00, 
occurs directly as a result ofCD28 ligand binding and is involved in transducing the signal delivered 
through CD28 by accessory cells that express the B7/BB1 receptor.  Thus, this particular form 
of signal transduction may be relevant to lymphokine production and, potentially may provide 
a means to study the induction of self-tolerance,  given the putative role of the costimulatory 
signal in the induction of T  cell activation or anergy. 
T 
he activation of T lymphocytes requires both an antigen- 
specific signal that is delivered by the TCR/CD3 com- 
plex, and the delivery of accessory cell-derived costimula- 
tory signals (1, 2). While the TCR mediates the specificity 
of a T  cell-initiated immune response,  the presence or ab- 
sence of the costimulatory signal regulates lymphokine gene 
expression (3, 4). The functional outcome of T cell activa- 
tion also appears to depend on the nature of the accessory 
cell-derived costimulatory signal.  For example, it has been 
proposed that specific tolerance can be induced by antigen 
encountered in the absence of a costimulatory signal (1-3). 
CD28, a 44-kD glycoprotein expressed as a homodimer 
on the surface of most peripheral blood T cells, is a hypothetical 
receptor for such an accessory signal (5). When CD28 + cells 
are activated with antigen, mitogenic lectins, anti-TCR/CD3 
mAbs, or by PMA, costimulation with CD28 mAbs leads 
to enhanced production of several lymphokines (I1.-2, GM- 
CSF, IFN-%  and TNF-oe)  and increased cellular prolifera- 
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identified as B7/BB1 (8), a cell surface glycoprotein present 
on activated B cells (9, 10) and IFN-3,-stimulated monocytes 
(11). Recent experiments in which CD28 was ligated with 
B7/BB1 indicate potent functional effects of CD28-B7/BB1 
interaction that are similar to previous studies that used mAbs 
to bind the CD28 receptor (12-14). 
A major issue that remains unresolved is the nature of the 
signal  transduction pathway utilized by CD28.  Triggering 
of the TCR leads to rapid tyrosine phosphorylation on a va- 
riety of substrates,  including phospholipase C 3'1, and pro- 
vides second messengers  that activate protein kinase C  and 
raise the intracellular calcium concentration (15). In contrast, 
CD28  stimulation with bivalent mAb does not appear  to 
be accompanied by increases in [Ca2+]i and protein kinase 
C activation (5, 16). Pharmacologic agents also appear to dis- 
tinguish between signal transduction by the TCR and by 
CD28,  in that TCR-mediated signal transduction is sensi- 
tive to the effects of cyclosporine and agents that raise intra- 
cellular cAMP concentration, while CD28-mediated effects 
are resistant (16-18). Furthermore, signal transduction through 
the TCR appears to require expression of the CD45 tyrosine 
phosphatase (19) while CD28 can function independently of 
CD45 expression  (20). 
It has been demonstrated recently that tyrosine phosphory- 
lation has a pivotal role in the early signal transduction events 
after engagement of the TCR (21, 22).  With regard to the 
CD28-associated signal transduction pathway, however, the 
potential involvement of tyrosine phosphorylation has not 
been extensively studied. The present study reports that stim- 
ulation ofJurkat T cells and normal T cells with anti-CD28 
mAb induces tyrosine phosphorylation of several substrates. 
CD28-induced tyrosine phosphorylation was strongly en- 
hanced by prestimulation of cells with anti-CD3 mAb or 
with phorbol esters. The interaction of cells expressing the 
B7 molecule with T cells induced prolonged tyrosine phos- 
phorylation of one of these substrates.  These effects were 
specific as mAbs identifying other accessory molecules such 
as CD5 and MHC class I molecules could not induce tyro- 
sine phosphorylation of this substrate.  Finally, the induction 
of tyrosine phosphorylation by CD28 differed from antigen- 
induced signal transduction in that it was independent of ex- 
pression of the TCR. 
Materials  and Methods 
mAbs.  Anti-CD3  mAb G19-4 (IgG1), anti-CD28 mAb 9.3 
(IgG2a), anti-CD5 mAb 10.2 (IgG2a), and anti-CD45 mAb 9.4 
(IgG2a) were produced, purified, and in some cases, biotinylated 
as described previously (7, 16). Anti-B7 mAb 133 (IgM) was de- 
scribed previously and the dilutions of ascites used are indicated 
(23).  Anti-CD3  mAb  OKT3  (IgG2a) was  absorbed to  goat 
anti-mouse IgG covalently linked to microspheres (Kirkegaard & 
Perry Laboratories, Inc., Gaithersburg, ME)), by incubation of a 
1/10  s dilution of pooled ascites with 107 beads/ml in HBSS at 
room temperature, followed by extensive washing. 
Cells.  The CD28 + subset of T ceUs was isolated from periph- 
eral blood T lymphocytes by negative selection using immunoab- 
sorption with goat anti-mouse Ig--coated  magnetic particles  as pre- 
viously described (17). This resulted in a population of resting T 
cells that was >99%  CD3 § and that did not contain CD2+/ 
CD3- cells such as NK cells. The Jurkat T leukemia  cell line E6-1 
was a gift from Dr. A. Weiss (University of California, San Fran- 
cisco) and maintained in complete media, i.e., RPMI 1640 con- 
taining 2 mM t-gtutamine, 50/~g/ml gentamycin, and 10% FCS 
(HyClone Laboratories, Logan, UT).  In some instances, T cells 
or Jurkat cells were cultured in complete media, or in complete 
media with 5 ng/ml PMA (Sigma Chemical Co., St. Louis, MO) 
or OKT3 beads (+  5 beads/cell) before experiments. The Jurkat 
J32 cell line (CD2 +  ,CD3 +  ,CD28  +) has been described (24). J32 
variants (CD2 +  ,CD3-,CD28 +) were derived by 3, irradiation-in- 
duced mutagenesis  and immunoselection  (24); one such cloned mu- 
tant, J32-72.4 is stable in culture. The surface receptor expression 
of these cells was quantitated by indirect immunofluorescence  and 
analyzed by flow cytometry. The mean log fluorescence  intensity 
for each sample was determined and was converted  into linear rela- 
tive fluorescence  units (AFL) by the formula AFL  =  IO[(E-C)/D]; 
where E is the mean log fluorescence  intensity of the experimental 
antibody sample, C is the mean log fluorescence  intensity of the 
control antibody sample, and D is 50 channels/decade. For the 
TCR/CD3 and CD28 receptors, AFL of the J32 cells was 27.0 
and 57.0, and for the J32-74.2 cells 1.1 and 40.7. Northern blot 
analysis ofJ32-72.4 revealed  no detectable TCR-~ mRNA, while 
the expression  of the TCR-ce, CD3~,/~, and e, and TCR ~'mRNA 
was similar to that of the parental  J32 cells (our unpublished data). 
B7 Transfection of CHO Cells.  CHO cells were transfected  with 
B7 cDNA as previously  described (14). These calls have  previously 
been shown to stimulate lymphocyte  proliferation  and lymphokine 
secretion in a manner that mimics CD28 mAb-induced T cell acti- 
vation (13, 14). Transfected  CHO ceils showing no B7 expression 
were recloned and are referred to as CHO-B7-. CHO cells were 
detached from tissue culture plates by incubation in PBS with 0.5 
mM EDTA for 30 min and fixed in 0.4% paraformaldehyde  as pre- 
viously described (14). Fixed CHO-B7- cells were used as con- 
trol ceils. 
Immunoblot Analysis of  Protein Tyrosine Phosphorylation.  Details 
of the immunoblot assay  with antiphosphotyrosine  antibodies  have 
been described dsewhere (25, 26). Calls were suspended at 5-10 
x  107 cells/ml in reaction media, i.e., HBSS containing 0.8% FCS 
and 20 mM Hepes at 37~  at time -3 min and stimulated at time 
0 min. mAbs  were used at 10/~g/ml final  concentration. For cross- 
linking, biotinylated mAbs were incubated with cells for 5-8 min 
at room temperature, the cells prewarmed at time  -3 min, and 
stimulated with avidin (Sigma Chemical Co.) at a final concentra- 
tion of 40/~g/ml at time 0. Stimulation was terminated by the 
addition of ice-cold 10 x lysis  buffer, yielding a final concentration 
of  0.5% Triton X-100 (26). After lysis  at 4~  nuclei were pelleted 
and postnudear  supernatants were subjected to SDS-PAGE on a 
7.5%  gd,  transferred to polyvinylidene difluoride microporous 
membrane (Millipore, Bedford, MA), and the membranes probed 
with aff~ity-purified antiphosphotyrosine  antibodies, labeled  with 
12sI staphylococcal  protein A (ICN,  Irvine, CA) and exposed to 
x-ray film. 
Results 
Herbimycin  A  Prevents CD28-stimulated  11.,2 Production. 
Previous studies have shown that three distinct biochemical 
signals, provided by phorbol esters, calcium ionophore, and 
ligation of the CD28 receptor with mAb,  are required to 
cause optimal II_,2 secretion (27). Cells cultured in the pres- 
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Figure 1.  The effect  of  herbimycin  A on CD28-stimulated  IL-2  produc- 
tion. T cells  were  cultured  overnight  in the absence (open bars) or presence 
O~lled  bars)  of herbimycin  A (1/~M). The cells were then  cultured for a 
further  24 h in the presence  of  medium,  immobilized  anti-CD3  mAb (G19- 
4), PMA (3 rig/m1) (P), or PMA plus ionomycin  (150 ng/ml) (P+/) in 
the presence or absence of soluble anti-CD28 mAb 9.3 (1/~g/ml). Cell- 
free supernatant  was collected  and serial dilutions  were analyzed  for Ib2 
content  by  bioassay  as described  (27). Cells  cultured  in PMA, ionomycin, 
or 9.3 mAb only  produced <10 U/ml of IL-2. 
ence PMA, ionomycin, or CD28 mAb alone produced no 
detectable IL-2  and, as previously reported (27, 28), stimula- 
tion of the CD28 receptor strongly upregulated IL-2 produc- 
tion of T cells stimulated with immobilized anti-CD3 mAb, 
PMA, or PMA plus ionomycin (Fig. 1). To address the poten- 
tial role of tyrosine kinases in CD28-triggered signaling, we 
investigated the effect of herbimycin A, an inhibitor of the 
src family  protein tyrosine kinases (29), on the CD28-triggered 
enhancement of II.-2 production. The CD28 mAb mediated 
enhancement of IL-2 production in response to stimulation 
with immobilized anti-CD3, or PMA was nearly completely 
inhibited in the presence of herbimycin A. In contrast, I1.-2 
secretion mediated by PMA plus ionomycin stimulation was 
largely resistant to herbimycin (Fig.  1). 
Disruption of the proximal signaling pathway triggered 
through CD3 could potentially  explain the effect of  herbimycin 
on cells stimulated with anti-CD3 and anti-CD28. Consis- 
tent with this, CD3-triggered II.-2 production was previously 
shown to be exquisitely sensitive to herbimycin A (21). How- 
ever, II.72  production induced with the combination of PMA 
plus ionomycin or PMA plus CD28 stimulation permits, in 
principle, the ability to isolate the CD28 signal for testing 
the effect of herbimycin A. PMA plus anti-CD28-stimulated 
IL-2 production was sensitive to the effects of herbimycin A 
while, as noted above, PMA plus ionomycin-stimulated  I1:2 
secretion was resistant to the effects of herbimycin A. The 
Figure 2.  CD28  mAb induces  protein  tyrosine  phosphoryhtion  in PMA- 
treated  Jurkat E-6 cells but not in untreated  Jurkat E-6 cells.  Jurkat E-6 
cells were cultured  for 2 d in the presence or absence of PMA (5 ng/ml). 
After washing, 107 cells in 120/~i were stimulated  with reaction  media 
(control), anti-CD3 mAh (G19-4), anti-CD28  mAb (9.3), or crosslinked 
anti-CD28 mAb (9.3) (final  concentration, 10 ~tg/ml). For crosslinking, 
biotinylated mAb was added at time -10 rain, followed  by avidin (40 
/~g/ml) at time zero. After  2 rain, the reaction was terminated  with ice- 
cold  lysis  buffer  and posmuclear  supernatants  were  resolved  by SDS-PAGE 
electrophoresis, transferred  to immobihn, and immunoblotted  with an- 
tiphosphotyrosine,  followed  by 12SI-protein  A and autoradiography,  as de- 
scribed in Materials  and Methods.  The position  of  molecular  mass  markers 
are shown on the right; arrowheads to the left indicate  the position of 
pp75 and of ppl00. 
combination  of  PMA  plus  ionomycin plus  anti-CD28- 
stimulation resulted in  more  II.-2 secretion than optimal 
amounts of PMA plus ionomycin, consistent with previous 
reports (27, 28). However, in the presence of herbimycin A, 
PMA plus ionomycin plus CD28-stimulated cells produced 
approximately equivalent amounts of I1.-2 as cells stimulated 
in the absence of herbimycin with PMA plus ionomycin. To- 
gether, the above results suggest that the function of both 
the TCR and CD28 receptors  are sensitive  to herbimycin, 
and further suggest the independent effects of these three re- 
agents on II.-2 gene expression  (27,  28). 
Crosslinking of the CD28 Receptor by Monoclonal Antibody 
Induces Protein Tyrosine  Phosphorylation in PMA-treated  Jurkat 
and Not in UnstiraulatedJurkat  Cells.  Given the above-func- 
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phosphorylation in CD28-mediated signal transduction was 
investigated by immunoblot analysis of postnuclear superna- 
rants of whole cell lysates of the T cell leukemia line Jurkat 
E6-1 (Fig. 2). In a previous report, increased tyrosine phos- 
phorylation could not be detected in resting T cells after cross- 
linking the CD28 receptor (30). Consistent with that report, 
no changes in tyrosine phosphorylation were detected in un- 
stimulated  Jurkat cells after the binding of bivalent or cross- 
linked CD28 mAb (Fig. 2, lanes 3 and 4). Previous studies 
have shown that CD28 stimulation alone does not result in 
lymphokine production in Jurkat cells or induce prolifera- 
tion of primary T  cells (31-33).  Engagement of CD28 by 
CD28 mAbs or by B7,  the natural CD28 ligand, delivers 
a costimulatory signal provided T cells are stimulated with 
PMA or with TCR/CD3 mAbs (5,  12-14).  We reasoned 
that CD28-induced protein tyrosine phosphorylation might 
only occur in the context of a costimulatory signal.  To test 
this hypothesis, Jurkat cells were cultured in PMA and then 
stimulated with anti-CD28 mAb. In these PMA-stimulated 
cells, crosslinking of CD28 for 2 min induced phosphotyro- 
sine  on substrates  migrating with approximate molecular 
masses of 47, 62, 75, 82, 100, 110, and 145 kD (Fig. 2, lane 
7). Bivalent CD28 mAb induced tyrosine phosphorylation, 
but to a lesser magnitude. In agreement with a previous re- 
port (26),  CD3 triggering of Jurkat cells induced tyrosine 
phosphorylation of pp56,  pp65, pp75,  ppl00,  pp110,  and 
pp145 in resting Jurkat cells (Fig.  2,  lane 2) and in PMA- 
treated Jurkat cells (data not shown). Of particular interest 
are pp75 and ppl00, (arrowheads), which are consistently phos- 
phorylated by CD28 stimulation in all conditions we have 
tested. 
CD28  Receptor Crosslinking  with  Monoclonal Antibody In- 
duces Protein Tyrosine Phosphorylation in Normal T Cells.  We 
performed similar experiments with highly purified periph- 
eral blood T  cells from normal human donors in order to 
determine if CD28 could increase tyrosine phosphorylation 
in nontransformed cells (Fig. 3). T cells were cultured with 
PMA for 6 h before CD28 stimulation. Cross[inking of CD28 
for 2 rain on PMA-treated cells induced the appearance of 
tyrosine phosphorylated substrates that migrated at 47,  75, 
and 100 kD (lanes I vs. 4). Again, pp75 and ppl00 were most 
prominent and consistently reproduced. 
The effects of CD28 stimulation observed after 24-48 h 
of PMA stimulation (not shown) were more pronounced than 
those seen after 6 h (Fig. 3). Ligation of CD28 by mAb on 
resting T cells caused the appearance of weakly detected tyro- 
sine phosphorylation (Fig. 4, left). The induction of increased 
responsiveness to anti-CD28 mAb stimulation by PMA is 
slow in that 4-6 h of PMA treatment are required to consis- 
tently observe CD28-induced tyrosine phosphorylation. Ex- 
Figure 3.  CD28 induces  protein  tyrosine  phosphorylation  in  PMA- 
stimuhted T cells. Peripheral blood CD28 § T cells were cultured in PMA 
(5 ng/ml) for 6 h. After washing, 107 cells were stimulated for 2 min with 
media (control),  anti-CD3 mAb (G19.4),  anti-CD28 mAb (9.3), cross- 
linked anti-CD28 mAb (9.3), or crosslinked anti-CD5 mAb (10.2). Cells 
were lysed and protein  tyrosine  phosphorylation  was determined  as de- 
scribed in Fig. 2. 
Figure 4.  Kinetics of CD28-triggered induction of protein tyrosine phos- 
phorylation in quiescent  T cells and in TCR-stimulated T  cell blasts. T 
cells were cultured overnight in medium (left) or in the presence of anti- 
CD3-coated beads (right).  The cells were recovered, and 8  x  106 cells were 
stimulated  with crosslinked anti-CD28 mAb for 0--5 rain  as indicated, 
the cells lysed, and protein  tyrosine  phosphorylation  determined  as de- 
scribed in  Fig. 2. 
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B7 + cells induces sustained tyrosine phos- 
phorylation of ppl00. CHO cells expressing 
B7 or not expressing  B7 were detached  from 
tissue culture plates and fixed with 0.4% 
paraformaldehyde  as described  in Materials  and 
Methods.  +  and  -  indicate  expression or 
nonexpression  of B7, respectively.  T cells  were 
cultured overnight  with PMA (5 ng/ml). (A) 
Tune course. 5 x 105 CHO-B7- or B7 + cells 
were added to 5 x  106 PMA-treated  T cells 
at time 0. The reaction  was terminated  with 
lysis  buffer  after  0-30 min. (Lane  I) T cells  were 
lysed  first  followed  by the addition  of  the CHO- 
B7 + cells. (B) Blocking with anti-B7 mAb. 
5 x  10  s CHO-B7- cells or B7 + cells were 
added to 5 x 106 PMA-treated  T cells  at time 
0. (Lanes 1 and 2) T cells were  lysed  first fol- 
lowed by the addition  of the CHO-B7- (lane 
I) or CHO-B7  + (lane  2) cells. (Lane  5) CHO- 
B7 + cells were incubated  with anti-B7 mAb 
133 (1/100 of ascites)  for 30 rain  before  adding 
them to the T cells (+*). After 20 min, the 
reaction  was terminated  and detergent-soluble 
proteins were  processed  further  as described  in 
Fig. 2. The data in A and B are derived  from 
two independent  experiments.  The position  of 
ppl00 is indicated. 
periments with cycloheximide  indicate that new protein syn- 
thesis is required for cells to become responsive to CD28 (data 
not shown). The specificity of the CD28-induced tyrosine 
phosphorylation was investigated by crosslinking CD5 with 
an isotype-matched mAb (Fig. 3, lane 5). Increased tyrosine 
phosphorylation on the 75-kD substrate was occasionally in- 
duced by CD5 crosslinking. In contrast, CD5 never induced 
tyrosine phosphorylation on ppl00.  Similarly,  crosslinking 
of the MHC dass I receptor also did not induce tyrosine phos- 
phorylation of this substrate (not shown). 
CD28 Receptor Crosslinking Induces Protein Tyrosine Phos- 
phorylation in  CD3-treated Normal  T  Cells.  The above ex- 
periments suggest that the CD28 receptor is relatively inac- 
tive in quiescent cells, and becomes responsive  consequent 
to protein kinase C activation. To determine whether TCK 
stimulation can also prime calls for the CD28 signal, T calls 
were cultured overnight in medium or with anti-CD3 mAb 
OKT3 adsorbed to microspheres  (Fig. 4). In this experiment, 
crosslinked CD28 mAb induced low-level tyrosine phosphory- 
lation on multiple substrates in resting T  cells that peaked 
2-5 min after CD28 stimulation. In contrast, CD28 mAb 
induced marked tyrosine phosphorylation in CD3-primed cells 
that was maximal within 1 rain. Thus, costimulation of T 
ceUs with and-CD3 augmented CD28-induced tyrosine phos- 
phorylation as manifested by an increased  magnitude of re- 
sponse and an accelerated  kinetics of response.  This induc- 
tion of  responsiveness to CD28 did not require DNA synthesis, 
as separate studies have shown that the T cell blasts used for 
these studies were in the late G1 phase of the cell cycle (data 
not shown). 
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CD28 Receptor-B7/BB1 Receptor Interaction Induces Specific 
Tyrosine Phosphorflation in T  Cells.  The above results indi- 
cate that CD28 mAb can increase tyrosine phosphorylation 
on a variety of substrates  on pre-activated T  calls. Previous 
studies have indicated that CD28 appears to deliver two bio- 
chemically distinct signals, depending on the degree of cross- 
linking (30). The unique functional properties  of CD28 mAb 
observed after stimulation of T  calls do not require highly 
crosslinked CD28  mAb  and are  obtained using intact or 
F(ab')2 CD28  mAb  (33).  Recent  studies have shown that 
CHO ceils expressing the CD28 ligand mimic the functional 
effects ofCD28 mAb (13, 14). These cells presumably repre- 
sent  a  more  physiologic means  to  study CD28  receptor- 
mediated  signal  transduction.  CHO-B7 +  cells  were  in- 
cubated with PMA-treated T ceils at a CHO/T cell ratio of 
1:10 for 5-30 min (Fig. 5 A). B7-transfected CHO calls not 
expressing B7  on the call  surface  (CHO-B7-  cells)  were 
used as controls. Before the stimulation, CHO cells were fixed 
with paraformaldehyde to decrease phosphotyrosine back- 
ground. Previous studies have indicated that this treatment 
leaves intact B7-CD28 interaction and the ensuing functional 
effects (14). For the time zero point, lysis buffer was added 
to the T cells first, immediately followed  by addition of CHO 
cells to the mixture (Fig.  5 A, lane I;  and/3, lanes  1 and 
2).  CHO-B7 + cells induced specific tyrosine phosphoryla- 
tion that was detected primarily on a substrate that migrated 
at 100 kD. The CHO-B7-induced tyrosine phosphorylation 
was detectable within 5 rain of stimulation (data not shown) 
and remained devated at plateau levels for at least  30 rain. 
CHO-B7-induced tyrosine phosphorylation was evident at Figure 6.  CD28 crosslinking induces tyrosine phosphorylation  of  ppl00 
in a CD3- Jurkat cell line. CD3+CD28 + and CD3-CD28 § Jurkat mu- 
tant cell lines were generated  as described in Materials and Methods.  107 
cells were stimulated  for 2 min with anti-CD3 mAb (G19-4), crosslinked 
CD28 mAb (9.3),  or crosslinked anti-CD5 mAb (10.2), as described in 
Fig.  2.  The position of ppl00 is indicated. 
Figure 7.  CD28-induced tyrosine phosphorylation  can be prevented by 
herbimycin  A. T  cells were  treated  overnight with PMA (5 ng/ml) in 
the presence of the indicated concentration  of herbimycin A or in control 
medium.  The cells were collected, washed, and 8  x  106 cells were stimu- 
lated with medh or with crosslinked anti-CD28 mAb for 2 min. Detergent- 
soluble  proteins  were processed as described in Fig.  2. 
a variety of CHO-T cell ratios, and has been consistently ob- 
served for only the 100-kD substrate.  CHO-B7-  cells did 
not induce tyrosine phosphorylation  of ppl00. The B7-induced 
tyrosine phosphorylation was dependent upon CD28-B7 in- 
teraction as preincubation of the CHO cells with anti-B7 
mAb prevented CHO-B7 induced ppl00 tyrosine phosphory- 
lation (Fig.  5 B, lanes 4 vs. 5).  B7-  CHO cells induced a 
slight increase in ppl00 tyrosine phosphorylation in some 
experiments, however, this was not consistently observed (Fig. 
5, A  and B). 
In other experiments, aUoantigen-induced T cell blasts were 
tested for CD28-induced tyrosine phosphorylation. T  cells 
were cultured for 8 d with allogeneic irradiated cells and then 
stimulated with CD28 mAb. Tyrosine phosphorylation that 
was most pronounced on the 75- and 100-kD substrates was 
observed (data not shown). Thus, CD28 stimulation of T 
cells preactivated with alloantigen, CD3 mAb, or PMA can 
induce tyrosine phosphorylation on a limited number of sub- 
strates  that are early in onset and brief in duration. 
CD28 Receptor-induced Tyrosine Phosphorylation Does Not 
Require Celt Surface Expression of the T Cell Receptor.  There 
is evidence that the costimulatory signal delivered by CD28 
is independent of the TCR. Such conclusions are based on 
studies of CD28-induced lymphokine  production in cell lines 
lacking expression  of the TCR (31). The observation that 
CD28-induced lymphokine  production is resistant to various 
immunosuppressive  agents while TCR-induced lymphokine 
production is  sensitive  also  suggested that  CD28-induced 
signal transduction might be independent of the TCR (16-18). 
The Jurkat J32  and J32-72.4  lines  were studied to  assess 
whether CD28-induced tyrosine phosphorylation was depen- 
dent on expression of the TCR. J32 cells have the wild-type 
phenotype (24) while J32-72.4 is a TCR-  mutant line that 
expresses 71% of the wild-type levels of the CD28 receptor 
(see Materials and Methods). CD28 mAb stimulation clearly 
induced ppl00 tyrosine phosphorylation in the TCR- line, 
although the level of tyrosine phosphorylation was less than 
in the parental J32 line (Fig.  6).  The decreased magnitude 
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by CD45 (Fig. 8). Consistent with previous results (34), cross- 
linking of CD45 alone caused increased tyrosine phosphory- 
lation of a 120-135-kD  substrate (Fig. 8, lane 2); this effect 
is also seen in CD28 plus CD45-treated cells. Thus, the above 
studies indicate that CD28-induced tyrosine phosphorylation 
is sensitive to an inhibitor of src family protein tyrosine ki- 
nases, and furthermore, that the CD45 protein tyrosine phos- 
phatase can prevent  CD28-induced  protein  tyrosine phos- 
phorylation. 
Figure 8.  CD28-induced  tyro- 
sine phosphorylation  can be pre- 
vented  by anti-CD45  mAb.  T cells 
were cultured overnight with 
PMA (5 ng/ml).  107 cells were 
incubated  for 10 rain with media 
(control), biotinylated  anti-CD45 
mAb (9.4), anti-CD28  mAb (9.3), 
or both. mAbs  were crosslinked 
with avidin  at time 0. The reac- 
tion was terminated  after 2 min. 
Immunoblot analysis with  an- 
tiphosphotyrosine antibodies of 
detergent-soluble proteins was 
performed  as described  in Fig. 2. 
of CD28-induced phosphorylation in the TCR-  line is most 
likely the result of decreased surface expression of CD28 in 
these cells.  TCR stimulation caused substantial stimulation 
of a variety of phosphoproteins in J32 cells, while, as expected, 
anti-CD3  stimulation of the TCR-  J32-72.4 line failed to 
induce significant tyrosine phosphorylation. In J32 cells the 
magnitude of the phosphorylation observed on ppl00 was 
nearly equivalent after TCR and CD28 stimulation. The sub- 
strates induced by CD28 stimulation all comigrated with CD3- 
induced substrates. However, there are many phosphorylated 
substrates after CD3 stimulation that are not detected after 
CD28  stimulation.  CD5  stimulation failed to cause ppl00 
tyrosine phosphorylation in either line. 
CD28-induced Tyrosine Phosphorylation Can Be Prevented by 
CD45 and by Herbimycin A.  Given that protein tyrosine ki- 
nase inhibitor herbimycin A could ef~ciently inhibit CD28- 
induced II.-2 secretion (Fig.  1),  we tested this inhibitor for 
effects on CD28-induced tyrosine phosphorylation. T  cells 
were cultured in PMA  and various concentrations  of her- 
bimycin A. Tyrosine phosphorylation induced by anti-CD28 
mAb was nearly completely prevented in herbimycin-treated 
cells (Fig. 7) under conditions that specifically inhibit CD28- 
induced IL-2 production (Fig.  1). 
The brief temporal course of CD28  mAb-induced tyro- 
sine phosphorylation (Fig. 4) suggests regulation by a phos- 
phatase.  To address  the effects of phosphatases  on CD28- 
mediated signal transduction, T  cells were cultured in PMA 
and then stimulated with crosslinked CD28, CD45, or CD28 
plus CD45 mAbs. CD28 erosslinking induced tyrosine phos- 
Discussion 
In the present study we have used phosphotyrosine im- 
munoblot analysis to show that ligation of the CD28 receptor 
induces increased  tyrosine  phosphorylation  on  several  de- 
tergent-soluble cellular substrates. Experiments with an in- 
hibitor ofsrc family tyrosine kinases, herbimycin A, suggest 
that the functional effects of CD28 stimulation on lymphokine 
gene expression require protein tyrosine phosphorylation. The 
tyrosine phosphorylation induced by the CD28 receptor differs 
in several  important aspects from that of the TCR.  TCR- 
induced tyrosine phosphorylation occurs in both resting and 
activated T  cells,  while CD28-induced tyrosine phosphory- 
lation occurs primarily in previously activated T  cells. Liga- 
tion of the TCR by antigen or by CD3 mAb induces tyro- 
sine phosphorylation of >12  substrates  (26),  while CD28 
ligation by antibody induces phosphorylation detectable on 
a more limited set of substrates. Separate experiments failed 
to demonstrate tyrosine phosphorylation of the TCR ~" chain 
(not  shown).  Most  striking  were  the  results  after  CD28 
receptor ligation by cell-bound B7, where phosphorylation 
was consistently detectable on only a single substrate.  The 
specificity of CD28-induced  tyrosine phosphorylation was 
shown by the failure of isotype-matched mAbs to two addi- 
tional T cell adhesion receptors, CD5 (Fig. 3) and MHC class 
I antigens (not shown), to induce tyrosine phosphorylation 
on ppl00. Thus, there are several cellular adhesion receptors 
that have "accessory"  functions on T  cells,  and yet do not 
activate the same biochemical signal transduction cascade as- 
sociated with  the CD28  receptor. 
Experiments using the Jurkat  E6-1  T  cell line indicated 
there is an absolute requirement for PMA pretreatment in 
order to  observe CD28-induced  tyrosine phosphorylation. 
In contrast, there was no requirement for cellular preactiva- 
tion in the Jurkat J32 line,  while, as noted above,  there is 
a relative requirement for PMA or TCR prestimulation of 
normal T  cells in order to induce CD28 responsiveness. The 
basis for the prestimulation requirement is not known at this 
time, although we have noted that new protein synthesis is 
required. Previous studies have shown that antigen treatment 
of T  cell clones causes  substantial  enhancement of CD28 
receptor expression (35), and in the case of primary T  cells, 
PMA treatment causes increased CD28 mRNA expression 
and increased surface CD28  expression (36).  However,  in- 
creased surface CD28  expression is unlikely to explain the 
requirement for new protein synthesis for CD28-induced signal 
957  Vandenberghe  et al. transduction, as Jurkat cells have brighter CD28 surface ex- 
pression than primary T cells, and yet have no detectable tyro- 
sine phosphorylation after CD28 stimulation. Thus, the coup- 
ling of the CD28 receptor to signal transduction likely involves 
the expression of some other protein in the signal transduc- 
tion pathway that is limiting or absent in resting T  cells, 
and is induced by TCR stimulation. 
The requirement for PMA or anti-CD3 pretreatment could 
indicate either that CD28-associated signal transduction re- 
quires a consequence of PKC activation, or alternatively, that 
depletion of PKC is required for the CD28 signal. The latter 
possibility is considered unlikely as only relatively low con- 
centrations of PMA are required, and furthermore, a more 
physiologic means of activation, anti-CD3, is capable of in- 
ducing CD28 responsiveness. In addition, immunoblot analysis 
of CD28-responsive cells indicates easily detectable amounts 
of PKC. 
Studies with Jurkat mutants further indicate that CD28- 
induced tyrosine phosphorylation (Fig. 6) and biologic func- 
tion (31) can occur in the absence of the TCR.  In this re- 
spect, CD28 appears  to be unique, in that other accessory 
molecules involved in T  cell activation such as CD2, Ly-6, 
Thy-1, and CD5 appear to require the presence of the TCR. 
The mechanism for the independence of the CD28 pathway 
remains unclear, and may indicate that the CD28 receptor 
is coupled to different kinase(s)/phosphatases  than is the TCR. 
This notion would be in accord with findings of Koretzky 
et al. (20), who found that Ib2 production induced by anti- 
CD28 mAb was independent of CD45 expression, while both 
CD2- and TCR-induced II-2 expression required CD45 ex- 
pression. The independence of the CD28-induced tyrosine 
phosphorylation from the TCR is also in accord with studies 
that indicated sensitivity of TCR-induced functional responses 
to cyclosporine, prostaglandin E2, 1,25-hydroxyvitamin D3, 
and cholera toxin, and resistance of the CD28 pathway to 
these agents (16-18,  37). 
In previous studies, we and others have failed to observe 
tyrosine phosphorylation after CD28 receptor stimulation 
(30). There appear to be several reasons for the differing results, 
including the failure to test appropriately "primed" T  cells 
and the fact that CD28 stimulation causes only a minor subset 
of substrate phosphorylation.  The inability in the present 
studies to consistently observe CD28 mAb-induced tyrosine 
phosphorylation with bivalent antibody is likely explained 
by the signal being at the limit of detection by our current 
assay  system.  However,  the  observation  that  cell-bound 
B7/BB1 receptor could activate T cell tyrosine phosphoryla- 
tion suggests that tyrosine phosphorylation results from CD28 
receptor-ligand interaction under physiologic conditions. 
The CD45 tyrosine phosphatase has previously been shown 
to prevent calcium mobilization induced by crosslinked CD28 
(38),  and in the current studies, we have found that under 
these conditions, CD28-induced tyrosine phosphorylation of 
ppl00 is prevented. This result may imply that CD28-induced 
tyrosine phosphorylation can be regulated by a tyrosine phos- 
phatase.  Under physiologic conditions, it is likely that phos- 
phatases  other than CD45 regulate CD28-mediated signal 
transduction, as CD28-induced lymphokine production has 
been shown to occur in CD45-negative Jurkat cells (20). 
The CD28 receptor has been shown to have potent effects 
on lymphokine production by several different mechanisms 
(28, 39), and postulated to have effects on thymic differentia- 
tion (40) and T cell anerg'y (3, 41). The relation of the CD28- 
induced tyrosine phosphorylation to these functional effects 
remains to be demonstrated in further studies. 
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